BECTON, DICKINSON AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 235.7 USD | +0.29% |
|
+0.42% | -3.35% |
| May. 10 | Exclusive-Biden to put tariffs on China medical supplies - sources | RE |
| May. 06 | Barclays Adjusts Price Target on Becton, Dickinson to $312 From $305, Keeps Overweight Rating | MT |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Annual 2022 Meeting ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
235.7
USD
Average target price
278.8
USD
Spread / Average Target
+18.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.35% | 68.11B | |
| -4.84% | 182B | |
| +0.56% | 110B | |
| +2.39% | 50.53B | |
| +9.36% | 44.8B | |
| +2.70% | 40.7B | |
| +24.51% | 32.3B | |
| +3.43% | 26.53B | |
| +13.67% | 25.02B | |
| -0.32% | 24.96B |
- Stock Market
- Equities
- BDX Stock
- News Becton, Dickinson and Company
- Transcript : Becton, Dickinson and Company - Shareholder/Analyst Call
